TScan Therapeutics to Present at 2024 Jefferies Global Healthcare Conference

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company listed on Nasdaq under the ticker TCRX, has announced its participation in the Jefferies Global Healthcare Conference. The event is scheduled to take place at the Marriott Marquis in New York City on June 5, 2024, at 11:00 a.m. Eastern Time.

The company, which specializes in developing T cell receptor (TCR)-engineered T cell (TCR-T) therapies for cancer treatment, will present its latest advancements and progress at the conference. The presentation will be accessible via a webcast on the "Events and Presentations" section of TScan’s website at ir.tscan.com. For those who cannot attend the live session, an archived replay of the webcast will be available on the company’s website for 90 days post-event.

TScan Therapeutics is dedicated to innovating cancer treatments, focusing particularly on TCR-T therapies. These therapies involve engineering T cells with specific T cell receptors to target and destroy cancer cells. The company's leading candidates, TSC-100 and TSC-101, are designed to treat hematologic malignancies and aim to prevent relapse after allogeneic hematopoietic cell transplantation. Alongside these, TScan is also developing therapies for a range of solid tumors.

A cornerstone of TScan’s strategy is its ImmunoBank, a comprehensive repository of therapeutic TCRs. This bank includes TCRs that recognize various targets and are compatible with multiple HLA types, allowing for the creation of personalized multiplex therapeutic TCR-Ts tailored to individual patients’ cancer profiles.

This forward-looking approach underscores TScan's commitment to addressing the complexities of cancer treatment by providing highly specialized and effective therapies. The development and expansion of the ImmunoBank are critical aspects of this mission, ensuring that the company can offer diverse and adaptable treatment options to meet the needs of patients with different types of cancer.

As part of its ongoing efforts to engage with the investor community and stakeholders, TScan Therapeutics leverages opportunities like the Jefferies Global Healthcare Conference to share its progress and future plans. The company’s presentation at the conference reflects its proactive approach to transparency and communication with investors.

In summary, TScan Therapeutics’ participation in the Jefferies Global Healthcare Conference highlights its advancements in TCR-T therapies and its dedication to developing cutting-edge cancer treatments. The company’s innovative approach, exemplified by its ImmunoBank, positions it as a significant player in the biopharmaceutical industry, committed to improving outcomes for cancer patients through personalized and effective therapies.